2021
DOI: 10.3389/fmed.2021.744050
|View full text |Cite
|
Sign up to set email alerts
|

Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

Abstract: Objective: To assess the safety and efficacy of low-dose everolimus maintenance therapy for tuberous sclerosis complex-related renal angiomyolipoma (TSC-RAML) patients that had previously undergone standard-dose treatment for a minimum of 6 months.Materials and Methods: In total, 24 patients with a definitive TSC diagnosis were enrolled from April 2018 – April 2019 at Xiangya Hospital, Central South University. All patients underwent low-dose everolimus maintenance therapy following standard-dose everolimus in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 17 publications
0
2
0
Order By: Relevance
“…These medications result in tumor shrinkage via inhibition of the mTOR pathway and subsequent tumor cell proliferation. Low-dose everolimus maintenance therapy represents an effective and tolerated approach to achieve TSC-associated AML control[ 44 - 46 ].…”
Section: Discussionmentioning
confidence: 99%
“…These medications result in tumor shrinkage via inhibition of the mTOR pathway and subsequent tumor cell proliferation. Low-dose everolimus maintenance therapy represents an effective and tolerated approach to achieve TSC-associated AML control[ 44 - 46 ].…”
Section: Discussionmentioning
confidence: 99%
“…Everolimus received accelerated FDA approval for rAML associated with TS, not in need of immediate surgery ( 41 ). Efficacy of everolimus was further studied at a lower maintenance dose of 5 mg in a subsequent study ( 42 ). Patients in this study received the standard “induction” dose of 10 mg followed by staying on a “maintenance dose” of 5 mg. All 24 patients enrolled in this study showed a response with decreased tumor volume and >50% reduction of volume was seen in 12 out of 24 patients.…”
Section: Management Of Raml: Different Scenarios and Latest Developmentsmentioning
confidence: 99%